IgA nephropathy is the most common glomerulonephritis worldwide and an important cause of ESRD.
IgA nephropathy (IgAN) has variable clinical presentation: it is of minimal clinical significance in many people and rarely may cause rapidly progressive kidney failure in others. Typical however in nephrology practice is a slowly progressive course, characterised initially by hematuria and persistent proteinuria before arterial hypertension, followed by a progressive fall in GFR, supervenes. Glomerulonephritis: "We suggest that patients with persistent proteinuria ≥1 g/d despite 3-6 months of optimized supportive care (including ACE inhibitor or angiotensin receptor blocker and blood pressure control) and GFR >50 mL/min receive a 6 month course of corticosteroid therapy (2C)." [1] The STOP-IgAN trial [2] published in July 2015 adds valuable new information which should influence the views of clinicians and researchers on this issue.
What does this important study show?
STOP-IgAN tested the hypothesis that immunosuppressive therapy slows kidney disease progression effect in individuals who are at high risk of progression (assessed by persistent proteinuria >0.75g/24hr) despite receiving maximal supportive care focused on tight blood pressure (BP) control and minimization of proteinuria through optimal renin-angiotensin system (RAS) blockade over a 6 month run-in phase.
Recruited from 32 German centers between February 2008 and October 2011, 309 patients completed the run-in phase. While all had proteinuria >0.75g/24hr at the start of the run-in phase, proteinuria fell and remained below 0.75g/24hr in 94 patients (30%), who, based on the protocol, were not randomized due to lower risk for progression. All patients entering STOP-IgAN had already been under the care of a nephrologist, and 95% were already receiving RAS blockade; even so 30% responded to optimisation of supportive therapy with a reduction in proteinuria below the threshold for randomization. In addition, 38 were ineligible due to proteinuria above 3.5 g/day, estimated glomerular filtration rate (eGFR) below 30 ml/min per 1.73m 2 , or a >30% increase in eGFR with run-in phase treatments. Of 177 eligible participants, the 162 who consented to randomisation either continued maximal supportive therapy or were randomized to one of two immunosuppressive regimens based on baseline eGFR. For those with eGFR > 60ml/min/1.73m 2 , the immunosuppressive regimen was the 'Pozzi' regimen [3] of intravenous and oral glucocorticoids for 6 months (methylprednisolone 1g daily for 3 days at the beginning of months 1,3, and 5 with oral prednisolone 0.5 mg/m 2 every 48 hours on the other days during the 6 month treatment period), then continuing supportive therapy alone until 36 months. For those with eGFR 30-59 ml/min/1.73m 2 , the immunosuppressive regimen described by Ballardie et al was used [4] (oral cyclophosphamide 1.5 mg/kg/day for 3 months followed by azathioprine 1.5mg/kg/day from month 4 to month 36 accompanied by oral prednisolone at an initial dose of 40mg/day tapered over 36 months). For both eGFR ranges, supportive therapy included RAS blockers with other anti-hypertensive agents as necessary to achieve a target BP < 125/75 mm Hg. If proteinuria remained >0.75g/24hr
despite BP control, the RAS blocker was increased to the maximum approved daily dose or to the highest dose at which patients did not have unacceptable side-effects.
Two primary end points were assessed at 36 months in hierarchical order: firstly, full clinical remission at the end of the trial (urine protein-creatinine ratio <0.2g/g and stable kidney function, defined by a fall in eGFR of less than 5ml/min/1. How does this study compare with prior studies?
Five RCTs of glucocorticoids in IgAN had been published by 2009 reporting a benefit either in short term reduction of proteinuria or protection from ESRD in those receiving glucocorticoids [3, [6] [7] [8] [9] . However the shared limitations of all these studies include the lack of uptitration of RAS blockade to minimise proteinuria, and the absence of a run-in period using supportive care alone before randomisation; this suggests that some of the benefit might be attributable to RAS blockade as much as to glucocorticoids.
An entry criterion in all these studies was GFR> 50ml/min/1.73m 2 .
Only one RCT had evaluated immunosuppression in IgAN with GFR 30-60ml/min/1.73m 2 ; this trialdemonstrated a benefit of cyclosphosphamide followed by azathioprine combined with oral glucocorticoids for 36 months. However in this study BP control was well above currently accepted goals, and the use of RAS blockade was not reported [4] . Other recent RCTs of immune modulating therapy have used supportive therapy as 'standard of care' including three small studies of mycophenolate; among these trials, one, conducted in a Chinese population, indicated benefit [10] while two others, both in European populations, did not [11, 12] .
STOP-IgAN is the first published RCT of immunosuppressive therapy in IgAN to include a 6 month run-in period before randomisation in which supportive care, including blood pressure control and antiproteinuric therapy using RAS blockade, was intensively optimised. It sets the standard for design of any study of a novel intervention in slowly progressive glomerulonephritis.
What should clinicians and researchers do? For clinical triallists designing RCTs of immunosuppressive and other novel therapies in IgAN, the impact of intensive supportive care and its low toxicity should ensure it is the standard of care to which all novel agents are added. Happily our review in January 2016 of published protocols of ongoing trials in IgAN using www.clinicaltrials.gov indicates the near universal requirement for supportive therapy for several months before selecting those with persistent proteinuria as candidates to be randomised to any novel intervention. Nevertheless the requirement for supportive care to be optimized as in STOP-IgAN is not always explicit in these protocols, and it is to be hoped that investigators will apply supportive care with the same rigor shown in STOP-IgAN in order to be able to test new therapies with confidence.
